New pill targets genetic weakness in advanced cancers
NCT ID NCT06560645
Summary
This early-stage study tested a new oral drug called PRT7732 in people with advanced or metastatic solid tumors that have a specific genetic change (SMARCA4 mutation). The main goals were to find a safe dose, see how the body processes the drug, and look for early signs that it might help control the cancer. The study was for patients whose cancer had progressed on standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Border Medical Oncology Research Unit
Albury, New South Wales, 2640, Australia
-
Brigitte Harris Cancer Pavilion
Detroit, Michigan, 48202, United States
-
Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, 135-8550, Japan
-
Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Kindai University Hospital
Sayama, Osaka, 589-8511, Japan
-
Linear Clinical Research Ltd
Nedlands, Western Australia, 6009, Australia
-
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York, 10065, United States
-
Monash Health
Clayton, Victoria, 3168, Australia
-
National Cancer Center
Goyang-si, Gyeonggi-do, 10408, South Korea
-
National Cancer Center Hospital
Chuo Ku, Tokyo, 104-0045, Japan
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Scientia Clinical Research Ltd
Randwick, New South Wales, 2031, Australia
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
Southern Highlands Cancer Centre
Bowral, New South Wales, 2576, Australia
-
Start Madrid-FJD, Hospital Universitario Fundacion Jimenez Diaz-Servicio de Oncologia
Madrid, 28040, Spain
-
Technische Universitat Dresden, Medizinlsche Fakultat Carl Gustav Carus Nationales Centrum fur Tumorerkrankungen Dresden, Early Clinical Trial Unit (NCT/UCC ECTU)
Dresden, Saxony, 01307, Germany
-
The Univerity of Osaka Hospital
Suita, Osaka, 565-0871, Japan
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
-
UNC Hospitals, The University of North Carolina Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
University Clinic Cologne, Clinic for Internal Medicine
Cologne, North Rhine-Westfalia, 50937, Germany
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia, 22903, United States
Conditions
Explore the condition pages connected to this study.